News | July 08, 2010

First Patient Enrolls in Heart Failure Trial

July 8, 2010 – Boston Scientific Corp. today announced enrollment of the first patient in its MultiSENSE clinical trial, which the company plans to use to develop a clinical alert identifying the early onset of worsening heart failure. The trial is designed to evaluate multiple physiologic sensors in the company’s Cognis cardiac resynchronization therapy defibrillators (CRT-Ds).

When combined with the company’s Latitude Patient Management System, CRT-D sensors would be able to monitor a patient outside of a clinical setting and permit the Latitude system to deliver early notification to the physician when the patient’s heart failure worsens.

“Heart failure is a complex disease and physicians use a number of diagnostics to assess a patient’s condition and disease progression,” said John Boehmer, M.D., medical director of the Heart Failure Program and professor of medicine, Penn State Hershey Medical Center and principal investigator of the MultiSENSE trial. “A multi-sensor design in an implantable device, with the predictive power of multiple data points, would enable physicians to take clinical action sooner to avoid hospitalization due to heart failure.”

Heart failure is a debilitating condition that affects a patient’s quality of life and life expectancy. It is a condition in which the heart weakens and gradually loses the ability to pump blood effectively. Approximately 22 million people worldwide suffer from heart failure and nearly one million new cases are diagnosed annually, making it the most rapidly growing cardiovascular disorder.

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init